Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study

Autor: Diego Bellido, MD, PhD, Pablo Abellán, MD, PhD, José Manuel Ruiz Palomar, MD, Rogelio Álvarez Sintes, MD, Andreu Nubiolae, MD, Virginia Bellido, MD, PhD, Gracia Romero, PhD

Publikováno v: Current Therapeutic Research, Vol 89, Iss , Pp 37-42 (2018)

ABSTRACT: Background: Basal insulin reduces fasting blood glucose levels, but postprandial blood glucose levels may remain higher. Traditional strategies with rapid insulin intensification can cause hypoglycemic episodes and weight gain. Glucagon-lik

Externí odkaz: https://doaj.org/article/747912a3475244439a12f88b0313e5a8

Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study

Autor: Virginia Bellido, Rogelio Álvarez Sintes, Andreu Nubiolae, Gracia Romero, Diego Bellido, José Manuel Ruiz Palomar, Pablo Abellán

Publikováno v: Current Therapeutic Research, Clinical and Experimental
CEU Repositorio Institucional
Fundación Universitaria San Pablo CEU (FUSPCEU)
Current Therapeutic Research, Vol 89, Iss, Pp 37-42 (2018)

Highlights • Adding lixisenatide to basal insulin was effective for uncontrolled type 2 diabetes. • Glycemic control improved and body weight lowered during 24 weeks of treatment. • These benefits were achieved with a low risk of hypoglycemia i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c28f8543d069e1dfbf86cdecc5e38a
https://pubmed.ncbi.nlm.nih.gov/30455779